Key Insights

Highlights

Success Rate

97% trial completion (above average)

Published Results

12 trials with published results (24%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

2.0%

1 terminated out of 51 trials

Success Rate

97.0%

+10.5% vs benchmark

Late-Stage Pipeline

39%

20 trials in Phase 3/4

Results Transparency

38%

12 of 32 completed with results

Key Signals

12 with results97% success

Data Visualizations

Phase Distribution

35Total
Not Applicable (7)
P 2 (8)
P 3 (6)
P 4 (14)

Trial Status

Completed32
Unknown8
Recruiting6
Enrolling By Invitation1
Not Yet Recruiting1
Active Not Recruiting1

Trial Success Rate

97.0%

Benchmark: 86.5%

Based on 32 completed trials

Clinical Trials (51)

Showing 20 of 20 trials
NCT00106925Recruiting

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

NCT06939751Recruiting

OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

NCT06532890Recruiting

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

NCT05689905Completed

Immunologic Risk of Pregnancy in Women With Lung Transplantion : a National Multicentric Study

NCT00619528Not ApplicableCompleted

HLA-Identical Sibling Renal Transplant Tolerance

NCT07347353CompletedPrimary

Molecular HistoMx Assessment for Kidney Transplant Rejection and Management

NCT07316829Active Not RecruitingPrimary

TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS

NCT06982404Recruiting

ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Transplant Biopsies - A Pilot Study

NCT05285878Phase 2Enrolling By Invitation

Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT04851145Not ApplicableCompleted

Mass Spectrometry-based Proteomics in Microvascular Inflammation Diagnosis in Kidney Transplantation.

NCT05333367Not ApplicableRecruiting

MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy

NCT06676696Phase 4Recruiting

Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure

NCT06281587CompletedPrimary

Pathogenetic Risk Factors for Corneal Graft Rejection

NCT04488094Phase 2CompletedPrimary

Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation

NCT05913583UnknownPrimary

Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection

NCT05072951UnknownPrimary

Urine Biomarker for Kidney Transplant Rejection

NCT00807144Phase 4Completed

Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation

NCT01147302Phase 2CompletedPrimary

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

NCT00476164Phase 4Completed

Study of Rituximab to Treat Chronic Renal Transplant Rejection

NCT00001858CompletedPrimary

Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants

Scroll to load more

Research Network

Activity Timeline